Prota Therapeutics, a Melbourne, Australia-based biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, raised US$21M in equity and debt funding.
The round was led by SPRIM Global Investments.
The company intends to use the funds to accelerate its Phase 3 clinical investigation of PRT120 oral therapy for peanut allergy.
Led by Executive Chairman Kelly Constable, Prota Therapeutics is a biotech company established in 2016 to develop and commercialize novel oral immunotherapy treatments for food allergy. Prota’s technology is based on over 15 years of research led by Professor Mimi Tang at the Murdoch Children’s Research Institute (MCRI). The company holds intellectual property covering the proprietary food immunotherapy technology developed at the MCRI.
FinSMES
17/01/2024